Navigation Links
Lauren Sciences LLC's research team at Ben-Gurion University awarded Campbell Foundation grant to develop a V-Smart therapeutic for neuro-HIV
Date:7/10/2012

New York, N.Y., July 10, 2012 -- Lauren Sciences LLC, a privately-held biotechnology company furthering development of its new V-Smart nanovesicle platform technology, announced today the award of a grant from The Campbell Foundation to its research team at Ben-Gurion University. The grant from Campbell will support development of the novel V-Smart nanovesicles for systemic delivery of tenofovir across the blood brain barrier (BBB) to the brain for treatment of neuro-HIV. Tenofovir is one of the most frequently used antiretroviral drugs in the multi-drug treatment of HIV infection. However, since tenofovir does not cross the BBB following systemic administration, the treatment is not effective against viral reservoirs in the central nervous system (CNS). The persistence of HIV in the CNS (called, neuro-HIV) is a major contributor to HIV-associated cognitive impairment and is perceived to be a major cause of the inability to completely control systemic HIV despite long-term highly active anti-retroviral treatment (HAART).

"On behalf of our research team at Ben-Gurion University, we thank The Campbell Foundation for this award," said Susan Rosenbaum, Esq., Chairman and Chief Executive Officer of Lauren Sciences. "The Campbell Foundation's award provides an opportunity to develop our innovative V-Smart drug delivery system for neuro-HIV and it recognizes the strong potential of our delivery system to overcome the challenge of developing drugs that cross the blood brain barrier."

"One of our Foundation's major goals is to find a disease-modifying therapy for HIV/AIDS," said Ken Rapkin, Program Officer of The Campbell Foundation. "The challenges associated with the delivery of HIV drugs through the blood brain barrier represent a critical unmet need in the field of AIDS research."

"Optimized V-Smart vesicles formulated with tenofovir has promise as an effective new treatment for patients," said Irwin Hollander, Ph.D., Vice President, Research and Development, Lauren Sciences. "We hope it will be able to stop proliferation of, or even help eradicate, the neuro-HIV that is presumed to cause cognitive impairment and systemic HIV reinfection in patients under long-term treatment. It is anticipated that our successful delivery of tenofovir to the brain will lead to future efficacy studies in neuro-HIV pre-clinical models and, thereafter, clinical studies in patients with HIV."

"Our pre-clinical studies so far demonstrate that our novel V-Smart nano-sized vesicles encapsulate small molecules, peptides, proteins and nucleic acids, transport them across the BBB and release their encapsulated contents in the brain," said Eliahu Heldman, Ph.D., Professor Emeritus at Ben-Gurion University and Chief Scientific Officer of Lauren Sciences LLC. "Our goal is to target the areas in the brain that are affected by HIV and reduce the viral load in those brain regions. The success of this project should provide more effective treatment for AIDS patients and improve their lives."


'/>"/>

Contact: Susan Rosenbaum
srosenbaum@laurensciences.com
212-737-0455
Lauren Sciences LLC
Source:Eurekalert

Related medicine news :

1. Washingtons Life Sciences Discovery Fund awards commercialization grants
2. Hutchinson Center president elected to American Academy of Art and Sciences
3. Ivy Neurological Sciences Internship program funded at TGen
4. UT MD Anderson President Ronald DePinho elected to National Academy of Sciences
5. UCSC physicist Alexander Sher named Pew Scholar in the Biomedical Sciences
6. Novel Natural Sciences Repository Opens Web Portal
7. New Anthropology and Archaeology Resources Published at Sciences Social Network
8. Natural Sciences Repository Publishes Chromatography and Acidic Compounds Resources
9. UCLA Brain Injury Research Center gets NCAA funding for research on sports concussions
10. NIH awards $20 million over 5 years to train next generation of global health researchers
11. Researchers develop a new cell and animal model of inflammatory breast cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/21/2017)... ... , ... Phytocéane invites you to take an exotic journey deep ... with ZANZIBAR SHOWER GEL. Inspired by the beauty of Zanzibar, a Tanzanian archipelago off ... vegetal coral to create this gentle, crystal-clear shower gel to cleanse the body and ...
(Date:1/21/2017)... ... January 21, 2017 , ... Northern California Medical Associates ... joined their multi-specialty medical group. The dermatology practice provides general dermatologic treatment, outpatient ... to add this excellent dermatology practice to our group’s medical services,” explains NCMA ...
(Date:1/21/2017)... , ... January 21, 2017 , ... In the United ... individuals experience the freedom of recovery, they often feel shame for having struggled with ... stress disorder (PTSD). In the workshop, “Rising Strong in Life After an Eating Disorder” ...
(Date:1/20/2017)... ... January 20, 2017 , ... Spectrum Aquatics Launches New ADA Portable Motion Trek BP ... Since the lift is mounted on wheels, it can be wheeled out of the way ... to fasten to the deck. "We have transformed the feedback from customers into specific enhancements ...
(Date:1/20/2017)... (PRWEB) , ... January 20, 2017 , ... Yisrayl Hawkins, Pastor and Overseer at The ... bible in homes across the world. Yisrayl says this generation is a time like no ... to turn to the Bible. , Yisrayl says he does not want to sound like ...
Breaking Medicine News(10 mins):
(Date:1/21/2017)... -- Research and Markets has announced the addition of ... Route Of Administration, End User - Forecast to 2025" report ... ... a CAGR of around 7.8% over the next decade to reach ... analyzes the global markets for Advanced Drug Delivery across all the ...
(Date:1/20/2017)... Stock-Callers.com today evaluates the following Drug ... Novo Nordisk A/S (NYSE: NVO ), Sucampo Pharmaceuticals ... Inc. (NASDAQ: PTX ). These stocks belong to ... , 2017, finishing near its session lows. As per a ... while shares of health care companies in the S&P 500 ...
(Date:1/20/2017)... January 20, 2017 Avillion LLP, a co-developer ... Mark Weinberg , MD MBA as Chief Medical Officer. Dr ... USA . ... Dr Weinberg has spent more than 17 years as a ... companies to micro-cap biotech. Over the course of his career, he ...
Breaking Medicine Technology: